You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS was associated with lower 30- and 60-day mortality rates compared to 7+31,a

30- and 60-day overall all-cause mortality in secondary AML patients aged 60-75 (safety populationb)1

30-day overall all-cause mortality with VYXEOS treatment
60-day overall all-cause mortality with VYXEOS treatment
  • 9 patients each in the VYXEOS arm (6%) and control arm (6%) had a fatal adverse reaction on treatment or within 30 days of therapy that was not in the setting of progressive disease1
  • 8 patients in the control arm (5%) died within 30 days of treatment due to progressive leukemia1
  • Fatal adverse reactions in the VYXEOS arm included infection, CNS hemorrhage, and respiratory failure1

Prolonged time to neutrophil and platelet recovery with VYXEOS1

Time to recovery of absolute neutrophil count and platelets may be prolonged with VYXEOS and require additional monitoring1

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.